放射性抵抗性直肠癌的预测生物标志物：系统评价。
Predictive biomarkers in radioresistant rectal cancer: A systematic review.
机构信息
Department of Oncology, Aalborg University Hospital, Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
出版信息
Crit Rev Oncol Hematol. 2023 Jun;186:103991. doi: 10.1016/j.critrevonc.2023.103991. Epub 2023 Apr 13.
BACKGROUND AND AIMS
The treatment of locally advanced rectal cancer often consists of neoadjuvant chemoradiotherapy followed by surgery. However, approximately 15% of patients show no response to this neoadjuvant chemoradiotherapy. This systematic review aimed to identify biomarkers of innate radioresistant rectal cancer.
METHOD
Through a systematic literature search, 125 papers were included and analyzed using ROBINS-I, a Cochrane risk of bias tool for non-randomized studies of interventions. Both statistically significant and nonsignificant biomarkers were identified. Biomarkers mentioned more than once in the results or biomarkers with a low or moderate risk of bias were included as the final results.
RESULTS
Thirteen unique biomarkers, three genetic signatures, one specific pathway, and two combinations of two or four biomarkers were identified. In particular, the connection between HMGCS2, COASY, and PI3K-pathway seems promising. Future scientific research should focus on further validating these genetic resistance markers.
背景和目的
局部晚期直肠癌的治疗通常包括新辅助放化疗，然后进行手术。然而，大约 15%的患者对这种新辅助放化疗没有反应。本系统评价旨在确定直肠癌固有放射抵抗的生物标志物。
方法
通过系统文献检索，共纳入 125 篇论文，并使用 ROBINS-I 进行分析，ROBINS-I 是一种针对干预措施的非随机研究的 Cochrane 偏倚风险工具。同时确定了具有统计学意义和无统计学意义的生物标志物。在结果中多次提到的生物标志物或具有低或中度偏倚风险的生物标志物被纳入最终结果。
结果
确定了 13 个独特的生物标志物、3 个基因特征、1 个特定途径和 2 个两个或四个生物标志物的组合。特别是 HMGCS2、COASY 和 PI3K 途径之间的联系似乎很有前途。未来的科学研究应集中于进一步验证这些遗传抗性标志物。
Zotero 插件